Publications by authors named "F Cosman"
Background: Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture. In the Abaloparatide Comparator Trial In Vertebral Endpoints study, bone mineral density improvements were significantly greater with abaloparatide compared to teriparatide at the total hip and femoral neck. We conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.
View Article and Find Full Text PDFArticle Synopsis
- The primary goal of osteoporosis management is to prevent fractures through individualized, goal-directed treatment plans.
- Effective treatment requires assessing a patient's fracture history, bone mineral density (BMD), and other major risk factors to determine the best course of action.
- Initial treatment should prioritize rapid fracture risk reduction for high-risk patients and take into account the likelihood of meeting BMD targets with either osteoanabolic or antiresorptive therapies.
Osteoanabolic-first treatment sequences are superior to oral bisphosphonates for fracture reduction and bone mineral density (BMD) gain. However, data comparing osteoanabolic medications, with the more potent antiresorptive, denosumab (DMAb), are limited. We analyzed FRAME and FRAME Extension data to assess BMD and fracture incidence in patients treated with romosozumab (Romo) followed by DMAb (Romo/DMAb) versus DMAb (DMAb/DMAb) for 24 months.
View Article and Find Full Text PDFArticle Synopsis
- Anabolic treatment is necessary for high-risk osteoporosis patients, but the current injectable medications are not well-accepted; this study tests a new oral PTH tablet alternative.
- In a 6-month, double-blind study with 161 postmenopausal women, the oral PTH showed dose-dependent effects on bone markers, with the highest dose (2.5 mg) significantly increasing bone formation markers and decreasing bone resorption markers.
- The 2.5 mg oral PTH tablets improved bone mineral density (BMD) at crucial sites (lumbar spine, total hip, and femoral neck) compared to placebo, and while some mild side effects occurred, no serious adverse events were reported.